Dr Lawrence C Sweet, MD | |
18161 W 13 Mile Rd, Suite C, Southfield, MI 48076-1113 | |
(248) 646-3131 | |
(248) 646-5871 |
Full Name | Dr Lawrence C Sweet |
---|---|
Gender | Male |
Speciality | Allergy & Immunology |
Location | 18161 W 13 Mile Rd, Southfield, Michigan |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255321287 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207K00000X | Allergy & Immunology | 4301022261 (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Lawrence C Sweet, MD 18161 W 13 Mile Rd, Suite C, Southfield, MI 48076-1113 Ph: (248) 646-3131 | Dr Lawrence C Sweet, MD 18161 W 13 Mile Rd, Suite C, Southfield, MI 48076-1113 Ph: (248) 646-3131 |
News Archive
People suffering from major depressive disorder, MDD, have reduced arginine levels, a new study from the University of Eastern Finland shows. Arginine is an amino acid which the body uses to produce, e.g., nitric oxide.
Scientists at the University of Pennsylvania School of Medicine discovered that a dietary antioxidant found in such vegetables as broccoli and cauliflower protects cells from damage caused by chemicals generated during the body's inflammatory response to infection and injury. The finding has implications for such inflammation-based disorders as cystic fibrosis (CF), diabetes, heart disease, and neurodegeneration.
A research team co-led by Dr. Stephen Scherer, Senior Scientist at The Hospital for Sick Children (SickKids) was awarded an $8.9 million grant today from the Global Leadership Round in Genomics & Life Sciences (GL(2)), which is part of the Ontario Research Fund (ORF) by the Ministry of Research and Innovation (MRI).
In a study that demonstrates the promise of cell-based therapies for diseases that have proved intractable to modern medicine, a team of scientists from the University of Wisconsin-Madison has shown it is possible to rescue the dying neurons characteristic of amyotrophic lateral sclerosis (ALS), a fatal neuromuscular disorder also known as Lou Gehrig's disease.
Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation.
› Verified 5 days ago
Dr. Thomas James Trueheart, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 21700 Northwestern Hwy, Suite 1290, Southfield, MI 48075 Phone: 248-395-2273 Fax: 248-395-3889 |